• Personalis flagged six clinical abstracts on its NeXT Personal ctDNA test scheduled for the 2026 ASCO meeting in Chicago on May 29–June 2.
• Future TRACERx podium data in early-stage non-small cell lung cancer is set to show that ultra-low ctDNA detection identifies patients at high relapse risk.
• Future VICTORI colorectal cancer poster results are expected to show the test can detect recurrence early in post-surgery surveillance.
• Additional posters across other solid tumors are slated to support broader clinical use in relapse monitoring and treatment-response assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605260600BIZWIRE_USPR_____20260526_BW794601) on May 26, 2026, and is solely responsible for the information contained therein.